119 related articles for article (PubMed ID: 34837478)
1. Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Narahara S; Watanabe T; Nagaoka K; Fujimoto N; Furuta Y; Tanaka K; Tokunaga T; Kawasaki T; Yoshimaru Y; Setoyama H; Oniki K; Saruwatari J; Tateyama M; Naoe H; Tanaka M; Tanaka Y; Sasaki Y
Hepatol Commun; 2022 May; 6(5):1198-1212. PubMed ID: 34837478
[TBL] [Abstract][Full Text] [Related]
2. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma.
Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X
Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Zhong J; Yu X; Dong X; Lu H; Zhou W; Li L; Li Z; Sun P; Shi X
Int J Mol Med; 2018 May; 41(5):2893-2900. PubMed ID: 29436591
[TBL] [Abstract][Full Text] [Related]
4. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis.
Zheng W; Yao M; Wu M; Yang J; Yao D; Wang L
J Transl Med; 2020 Feb; 18(1):81. PubMed ID: 32059741
[TBL] [Abstract][Full Text] [Related]
5. Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway.
Naik PP; Mukhopadhyay S; Praharaj PP; Bhol CS; Panigrahi DP; Mahapatra KK; Patra S; Saha S; Panda AK; Panda K; Paul S; Aich P; Patra SK; Bhutia SK
Life Sci; 2021 Jan; 264():118722. PubMed ID: 33160989
[TBL] [Abstract][Full Text] [Related]
6. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
Zhang J; Wu M; Xu Y; Song Q; Zheng W
Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
[TBL] [Abstract][Full Text] [Related]
7. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Gan H; Li L; Hu X; Cai J; Hu X; Zhang H; Zhao N; Xu X; Guo H; Pang P
Cancer Biol Ther; 2022 Dec; 23(1):1-14. PubMed ID: 36310384
[TBL] [Abstract][Full Text] [Related]
8. Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.
Xiu P; Xu Z; Liu F; Li Z; Li T; Zou F; Sun X; Li J
Dig Dis Sci; 2014 Aug; 59(8):1798-809. PubMed ID: 24671452
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin.
Chen D; Wang Y; Zhang K; Jiao X; Yan B; Liang J
Int J Mol Sci; 2012; 13(8):10594-10607. PubMed ID: 22949882
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Yang X; Liu J; Liang Q; Sun G
Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma.
Zheng W; Yao M; Sai W; Qian Q; Pan L; Qiu L; Huang J; Wu W; Yao D
Tumour Biol; 2016 Jan; 37(1):999-1008. PubMed ID: 26264614
[TBL] [Abstract][Full Text] [Related]
13. Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway.
Wei Q; Ren Y; Zheng X; Yang S; Lu T; Ji H; Hua H; Shan K
Bioengineered; 2022 May; 13(5):13919-13928. PubMed ID: 35719058
[TBL] [Abstract][Full Text] [Related]
14. Clusterin contributes to hepatitis C virus-related hepatocellular carcinoma by regulating autophagy.
Fu N; Du H; Li D; Lu Y; Li W; Wang Y; Kong L; Du J; Zhao S; Ren W; Han F; Wang R; Zhang Y; Nan Y
Life Sci; 2020 Sep; 256():117911. PubMed ID: 32504756
[TBL] [Abstract][Full Text] [Related]
15. Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.
Zhang X; Wu L; Xu Y; Yu H; Chen Y; Zhao H; Lei J; Zhou Y; Zhang J; Wang J; Peng J; Jiang L; Sheng H; Li Y
Cancer Lett; 2020 Jul; 481():32-44. PubMed ID: 32246956
[TBL] [Abstract][Full Text] [Related]
16. Secretory Clusterin as a Novel Molecular-targeted Therapy for Inhibiting Hepatocellular Carcinoma Growth.
Yao M; Sai W; Zheng W; Wang L; Dong Z; Yao D
Curr Med Chem; 2020; 27(20):3290-3301. PubMed ID: 31232234
[TBL] [Abstract][Full Text] [Related]
17. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
18. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
19. Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.
Wang X; Zou F; Zhong J; Yue L; Wang F; Wei H; Yang G; Jin T; Dong X; Li J; Xiu P
J Cancer; 2018; 9(8):1403-1413. PubMed ID: 29721050
[No Abstract] [Full Text] [Related]
20. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
